Skip to content
Search

Latest Stories

ABPI appoints Jessamy Baird as its Vice President Elect

The Association of the British Pharmaceutical Industry (ABPI) has appointed Jessamy Baird as Vice-President Elect of the ABPI.

Jessamy is Managing Director/Country Lead, Sanofi UK & Ireland. At Sanofi, Jessamy leads the UK organisation to chase the miracles of science to improve people's lives and transform the practice of medicine.


She will join and support ABPI President Elect Susan Rienow, UK Managing Director and Country President of Pfizer, in delivering her presidential priorities and support the ABPI in its mission to make the UK the best place in the world to research, develop and use the medicines and vaccines of the future.

Both Jessamy and Susan will formally take up their new roles on Thursday 25 May.

Jessamy Baird, ABPI Vice-President Elect and Sanofi UK & Ireland’s Managing Director/Country Lead, said: “The pharmaceutical industry is vital to the continued health and wealth of the UK, delivering innovative, life-saving medicines to the NHS and adding £37billon to the UK economy each year. I am proud to have been elected Vice-President by my peers during this crucial period and I look forward to working with the ABPI President to ensure the UK remains a competitive and innovative global life science leader.”

Susan Rienow, ABPI President and UK Managing Director of Pfizer said: “I look forward to working with Jessamy to help the industry navigate the many challenges and opportunities ahead, while always putting patients at the heart of everything we do.

Together, with ABPI colleagues, we will work to improve the commercial environment, ensure patients have access to new medicines, and drive meaningful progress within UK life sciences and beyond towards a more sustainable future.”

Richard Torbett, ABPI Chief Executive said: “We are thrilled to welcome Jessamy into her new role of Vice-President. Together Jessamy and Susan bring a wealth of industry experience and insight. I look forward to working with them both to achieve the ABPI’s shared vision of making the UK the best place in the world to research, develop and use the medicines and vaccines of the future.”

Jessamy began her career in healthcare research/health economics following her BSc. (Hons) in Health Sciences/Health Economics from University of Aberdeen. Since then, she has worked in roles that span the pharmaceutical industry, academia and the NHS.

Jessamy’s prior role within Sanofi was Director of Market Access, UKIE, supporting national and local healthcare access for patients to Sanofi medicines and vaccines. Before joining Sanofi in 2015, she worked at Eli Lilly Ltd in a range of director roles covering Real World Evidence, Market Access strategy and Health Technology Appraisal across Australia, Canada, Europe and Japan.

Jessamy has held Non-Executive/Board level roles in the NHS for more than 10 years, the most recent being Non-Executive Adviser for Hampshire and Isle of Wight Partnership, North Hants CCG, previously a Non-Executive Director at the Isle of Wight Healthcare NHS Trust, and also worked as Executive Director on the Trust Board of an NHS Foundation Trust providing mental health and community care across Hampshire.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less